Pradžia › Neuroblastoma › Texas
Neuroblastoma klinikiniai tyrimai Texas
15 tyrimai dėl Neuroblastoma ieško dalyvių vietose Texas.
Miestai Texas
Oficialus tyrimo tekstas (anglų kalba)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- ir dar 10
Renkami dalyviai3 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-10-02 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Renkami dalyviai2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-09-04 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Children's Medical Center, Dallas
Renkami dalyviai1/2 fazė
Iki 26 metų · Visoms lytims · Atnaujinta 2026-09-03 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
Renkami dalyviai1/2 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-09-03 · NCT06541262Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Renkami dalyviai2 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2026-09-03 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- ir dar 8
Renkami dalyviai3 fazė
365 Days – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
Renkami dalyviai2 fazė
12 Months – 21 Years · Visoms lytims · Atnaujinta 2026-08-12 · NCT05489887PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Renkami dalyviai1/2 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-07-22 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
- Texas Children's Hospital, Houston
Renkami dalyviai1 fazė
Amžius nuo 1 iki 24 · Visoms lytims · Atnaujinta 2026-07-21 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center, Fort Worth
Renkami dalyviai2 fazė
Amžius nuo 1 iki 31 · Visoms lytims · Atnaujinta 2026-07-20 · NCT06450041Neuroblastoma Biology Study
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center - Fort Worth, Fort Worth
Renkami dalyviaiStebimasis tyrimas
31 Days – 99 Years · Visoms lytims · Atnaujinta 2026-03-23 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- University of Texas Southwestern Medical Center, Dallas
Renkami dalyviai
Iki 17 metų · Visoms lytims · Atnaujinta 2026-02-10 · NCT06831552GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
- Texas Children's Hospital, Houston
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2025-09-19 · NCT03294954Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.